Abstract:DOK-1 and DOK-2 (DOK1/2) are closely related members of downstream of tyrosine kinase (DOK) family genes, which are found to be frequently rearranged in several hematopoietic cancers. However, the clinical implications of DOK1/2 in acute myeloid leukemia (AML) remain largely unknown. To investigate the clinical significance, real-time quantitative PCR (RQ-PCR) was carried out to detect DOK1/2 expressions in 125 de novo AML patients and 28 healthy controls. Real-time quantitative methylation-specific PCR (RQ-MS… Show more
“…DOK family genes disorders have been reported in many cancers [9] , [18] , [19] , [20] . Although DOK family genes expression is closely associated related with pathological progression and poorer prognosis in some tumors, there has been no comprehensive analysis of DOK family genes in different cancer.…”
Section: Discussionmentioning
confidence: 99%
“…Recent studies have shown that abnormal DOK gene expression is closely related to leukemia [9] , lung cancer [10] , gastric cancer [11] , colorectal cancer [11] , [12] , and breast cancer [13] , [14] . However, most of the studies are conducted in cell lines and/or animal models, and systematic studies have not been conducted in human tumors.…”
“…DOK family genes disorders have been reported in many cancers [9] , [18] , [19] , [20] . Although DOK family genes expression is closely associated related with pathological progression and poorer prognosis in some tumors, there has been no comprehensive analysis of DOK family genes in different cancer.…”
Section: Discussionmentioning
confidence: 99%
“…Recent studies have shown that abnormal DOK gene expression is closely related to leukemia [9] , lung cancer [10] , gastric cancer [11] , colorectal cancer [11] , [12] , and breast cancer [13] , [14] . However, most of the studies are conducted in cell lines and/or animal models, and systematic studies have not been conducted in human tumors.…”
“…Total RNA was extracted using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) and reverse transcribed into cDNA as described previously [26]. Real-time quantitative PCR (RT-qPCR) was performed using AceQ qPCR SYBR Green Master Mix (Vazyme Biotech Co., Piscataway, NJ, USA) on a 7500 Thermo cycler (Applied Biosystems, CA).…”
Section: Methodsmentioning
confidence: 99%
“…Real-time quantitative PCR (RT-qPCR) was performed using AceQ qPCR SYBR Green Master Mix (Vazyme Biotech Co., Piscataway, NJ, USA) on a 7500 Thermo cycler (Applied Biosystems, CA). Reaction conditions and PCR cycling were conducted as previously described [26], adjusting only for optimized primer annealing temperatures (60 °C). PCR primers were designed using Primer Premier 6 (Premier Biosoft, Palo Alto, CA, USA), and the primer sequences were listed in Additional file 1: Table S2.…”
Section: Methodsmentioning
confidence: 99%
“…To assess the changes in methylation level, real-time methylation-specific polymerase chain reaction (RQ-MSP) was employed using primers listed in Additional file 1: Table S2. PCR conditions were as described previously [26], except that the annealing temperature for methylation primers was 59 °C.…”
Background
Leukemia stem cell (LSC)-enriched genes have been shown to be highly prognostic in acute myeloid leukemia (AML). However, the prognostic value of tumor suppressor genes (TSGs) that are repressed early in LSC remains largely unknown.
Methods
We compared the public available expression/methylation profiling data of LSCs with that of hematopoietic stem cells (HSCs), in order to identify potential tumor suppressor genes in LSC. The prognostic relevance of
PCDH17
was analyzed on a cohort of 173 AML patients from The Cancer Genome Atlas (TCGA), and further validated in three independent cohorts (n = 339).
Results
We identified protocadherin17 (
PCDH17
) and demonstrated that it was significantly down-regulated and hypermethylated in LSCs compared with HSCs. Our analyses of primary AML patient samples also confirmed these deregulations. Clinically, low
PCDH17
expression was associated with female sex (
P
= 0.01), higher WBC (
P
< 0.0001), higher percentages of blasts in bone marrow (BM) and peripheral blood (PB) (
P
= 0.04 and < 0.001, respectively), presence of
FLT3
-internal tandem duplications (
P
= 0.002), mutated
NPM1
(
P
= 0.02), and wild-type
TP53
(
P
= 0.005). Moreover, low
PCDH17
expression predicted worse overall survival (OS) in four independent cohorts as well as in the molecularly defined subgroups of AML patients. In multivariable analyses, low
PCDH17
expression retained independent prognostic value for OS. Biologically,
PCDH17
expression-associated gene signatures were characterized by deregulations of EMT- and Wnt pathway-related genes.
Conclusions
PCDH17
gene was silenced by DNA methylation in AML. Low
PCDH17
expression is associated with distinct clinical and biological features and improves risk stratification in patients with AML.
Electronic supplementary material
The online version of this article (10.1186/s12967-019-1851-1) contains supplementary material, which is available to authorized users.
BackgroundDownstream of tyrosine kinase 6 (DOK6), which is specifically expressed in the nervous system, was previously recognized as an adapter only in neurite outgrowth. Recent studies also demonstrated the potential role of DOK6 in solid tumors such as gastric cancer and breast cancer. However, previous studies of DOK6 have not dealt with its roles in myeloid malignancies. Herein, we verified the promoter methylation status of DOK6 and further explored its clinical implication in de novo acute myeloid leukemia (AML).MethodsA total of 100 newly diagnosed adult AML patients were involved in the current study. DOK6 expression and methylation were detected by real‐time qPCR and methylation‐specific PCR (MSP), respectively. Bisulfite sequencing PCR (BSP) was performed to assess the methylation density of the DOK6 promoter.ResultsDownstream of tyrosine kinase 6 promoter methylation was significantly increased in AML patients compared to controls (P = .037), whereas DOK6 expression significantly decreased in AML patients (P < .001). The expression of DOK6 was markedly up‐regulated after treated by 5‐aza‐2′‐deoxycytidine (5‐aza‐dC) in THP‐1 cell lines. The methylation status of the DOK6 promoter was associated with French‐American‐British classifications (P = .037). There was no significant correlation existed between DOK6 expression and its promoter methylation (R = .077, P = .635). Interestingly, of whole‐AML and non‐APL AML patients, both have a tendency pertaining to the DOK6 methylation group and a significantly longer overall survival (OS) than the DOK6 unmethylation group (P = .042 and .036, respectively).ConclusionOur study suggested that DOK6 promoter hypermethylation was a common molecular event in de novo AML patients. Remarkably, DOK6 promoter methylation could serve as an independent and integrated prognostic biomarker not only in non‐APL AML patients but also in AML patients who are less than 60 years old.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.